๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Lianyungang
Clinical trial register · China

Clinical Trials in Lianyungang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Lianyungang

20 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Effect of Peripartum 40 Hz Audiovisual Stimulation on Postpartum Depression in Women Undergoing Elective Cesarean Section: A Randomized Clinical Trial
NCT07807462Depression, Postpartum
The First People's Hospital of Lianyungang
Not applicable
204
Lianyungang
2026-10-01
Not yet open
SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC
NCT07818304Non Small Cell Lung Cancer, Lung Neoplasms
The First People's Hospital of Lianyungang
Phase 2
61
Lianyungang
2026-10
Recruiting
Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery Disease
NCT07764094PCI, Drug-coated Balloon, Coronary Artery Disease
Nanjing First Hospital, Nanjing Medical University
Observational
500
Chuzhou, Tongling, Huai'an, Lianyungang, Nanjing, Xuzhou, Yixing
2026-09-01
Not yet open
Huanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
NCT07721012Patients With Irritable Bowel Syndrome With Diarrhea
Lei Yunshang Group
Phase 2
120
Beijing, Changsha, Daqing, Guangzhou, Hohhot, Lianyungang, Luoyang, Meihekou
2026-07-31
Not yet open
A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance
NCT07622550Metastatic Colorectal Cancer (CRC)
Jiangsu Cancer Institute & Hospital
Phase 2
80
Changzhou, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Wuxi, Xuzhou
2026-06-15
Not yet open
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
NCT07486479Acute Myeloid Leukemia (AML)
The First Affiliated Hospital of Soochow University
Phase 3
204
Hefei, Luoyang, Wuhan, Changzhou, Huai'an, Jingjiang, Lianyungang, Nanjing
2026-03-10
Recruiting
Effect of Tegileridine Versus Sufentanil as Analgesic Components on Opioid-Induced Cough During Anesthesia Induction
NCT07323043General Anesthetic Drug Adverse Reaction
The First People's Hospital of Lianyungang
Not applicable
190
Lianyungang
2026-01-15
Not yet open
Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients
NCT06683131Acute Myocardial Infarction (AMI)
The Affiliated Hospital of Xuzhou Medical University
Phase 4
1,160
Fuyang, Huai'an, Lianyungang, Nanjing, Suqian, Xuzhou, Beijing, Shanghai
2025-11-20
Active, closed
Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated Vaccine
NCT07232745Influenza
Jiangsu Province Centers for Disease Control and Prevention
Phase 4
60
Lianyungang
2025-10-12
Recruiting
Super High-pressure Balloon Versus Intravascular Lithotripsy to Prepare Severely Calcified Coronary Lesions
NCT07093788PCI, Coronary Arterial Disease (CAD), Calcified Coronary Lesions
Nanjing First Hospital, Nanjing Medical University
Not applicable
78
Lianyungang, Nanjing, Yixing
2025-09-01
Not yet open
Efficacy and Safety of Chinese Herbal HuoXue LiShui Formula for Chronic Subdural Hematoma
NCT06427980Chronic Subdural Hematoma
Beijing Tiantan Hospital
Not applicable
160
Beijing, Lianyungang
2025-02-01
Recruiting
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
NCT06775912SLE, Systemic Sclerosis, IIM, NMOSD
Nanjing Bioheng Biotech Co., Ltd.
Phase EARLY_PHASE1
18
Lianyungang
2025-01-03
Not yet open
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovyยฎ
NCT06633783Obesity
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Phase 3
370
Xuancheng, Huizhou, Luoyang, Nanyang, Zhengzhou, Yichang, Huaian, Lianyungang
2024-10-30
Recruiting
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
NCT06476093Non-Small-Cell Lung Cancer, Brain Metastases
The First People's Hospital of Lianyungang
Not applicable
46
Lianyungang
2024-07-01
Recruiting
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
NCT06758557Advanced NSCLC, Advanced Endometrial Cancer
Huabo Biopharm Co., Ltd.
Phase 1/2
282
Baoding, Harbin, Luoyang, Zhengzhou, Lianyungang, Shenyang, Jinan, Linyi
2024-01-31
Recruiting
Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection
NCT06051513Carbapenem-Resistant Enterobacteriaceae Infection
Southeast University, China
Not applicable
404
Hefei, Jinjiang, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Taizhou
2023-11-27
Recruiting
Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
NCT06141226Non-small-cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
148
Huizhou, Nanyang, Lianyungang, Weihai, Tianjin
2023-04-12
Active, closed
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642Chronic Obstructive Pulmonary Disease (COPD)
Hoffmann-La Roche
Phase 3
1,290
Guangzhou, Zhanjiang, Zunyi, Lianyungang, Beijing, Changchun, Changsha, Chengdu
2022-12-29
Active, closed
Anesthetic Effect of Ropivacaine on Local Infiltration Anesthesia in Arteriovenous Fistula Surgery
NCT07259772End Stage Renal Disease (ESRD), Arteriovenous Fistula Patency, Chronic Kidney Disease 5D
The First People's Hospital of Lianyungang
Phase 4
40
Lianyungang
2019-04-10
Active, closed
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197mCRPC
Pfizer
Phase 3
1,054
Hefei, Beijing, Fuzhou, Xiamen, Wuhan, Lianyungang, Nanjing, Nantong
2017-12-18
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/lianyungang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies with a site in Lianyungang.

How many clinical trials are recruiting in Lianyungang?

8 of the 20 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 8 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lianyungang), 20 studies
PhaseStudiesRecruitingShare
Not applicable6430%
Phase 24120%
Phase 34020%
Phase 43015%
Observational115%
Phase 1/2115%
Phase EARLY_PHASE1115%

Most active sponsors

Lead sponsors with the most studies (Lianyungang)
Lead sponsorStudiesRecruiting
The First People's Hospital of Lianyungang52
Nanjing First Hospital, Nanjing Medical University22
Beijing Tiantan Hospital10
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,10
Hoffmann-La Roche10
Huabo Biopharm Co., Ltd.11
Jiangsu Cancer Institute & Hospital10
Jiangsu Province Centers for Disease Control and Prevention10
Lei Yunshang Group10
Nanjing Bioheng Biotech Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.